Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
复制标题
DOI：
10.1056/nejmoa0800251
复制
发表时间：
2008-06-19
影响因子：
158.5
通讯作者：
Yee, Cassian
中科院分区：
文献类型：
--
作者：
Hunder, Naomi N.;Wallen, Herschel;Yee, Cassian
我们开发了一种分离和扩增自体CD 4 + T细胞克隆的体外方法，该方法对黑素瘤相关抗原NY-ESO-1具有特异性。我们将这些细胞输注到一名患有难治性转移性黑色素瘤的患者体内，该患者之前没有接受过任何预处理或细胞因子治疗。我们表明，转移的CD 4 + T细胞介导了持久的临床缓解，并导致对NY-ESO-1以外的黑色素瘤抗原的内源性反应。
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.